Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Non-Current Assets (2018 - 2025)

BioNexus Gene Lab's Non-Current Assets history spans 8 years, with the latest figure at $3.8 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $3.8 million for Q4 2025, up 26.66% from a year ago — trailing twelve months through Dec 2025 was $3.8 million (up 26.66% YoY), and the annual figure for FY2025 was $3.8 million, up 26.66%.
  • Non-Current Assets for Q4 2025 was $3.8 million at BioNexus Gene Lab, up from $2.0 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $4.0 million in Q3 2024 to a low of $2.0 million in Q3 2025.
  • The 5-year median for Non-Current Assets is $2.7 million (2022), against an average of $2.8 million.
  • The sharpest move saw Non-Current Assets skyrocketed 706.39% in 2021, then plummeted 49.58% in 2025.
  • Year by year, Non-Current Assets stood at $2.4 million in 2021, then grew by 12.12% to $2.7 million in 2022, then increased by 23.35% to $3.4 million in 2023, then fell by 10.43% to $3.0 million in 2024, then grew by 26.66% to $3.8 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $3.8 million, $2.0 million, and $3.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.